Global Public Health Partnering 2010 to 2020 provides the full collection of Public Health disease deals signed between the world’s pharmaceutical and biotechnology companies since 2010.
Most of the deals included within the report occur when a licensee obtains a right or an option right to license a licensor’s product or technology. More often these days these deals tend to be multi-component including both a collaborative R&D and a commercialization of outcomes element.
The report takes readers through the comprehensive Public Health disease deal trends, key players and top deal values allowing the understanding of how, why and under what terms companies are currently entering Public Health deals.
The report presents financial deal terms values for Public Health deals, where available listing by overall headline values, upfront payments, milestones and royalties enabling readers to analyse and benchmark the value of current deals.
The initial chapters of this report provide an orientation of Public Health dealmaking trends.
Chapter 1 provides an introduction to the report.
Chapter 2 provides an overview of the trends in Public Health dealmaking since 2010 covering trends by year, deal type, stage of development, technology type and therapeutic indication.
Chapter 3 includes an analysis of financial deal terms covering headline value, upfront payment, milestone payments and royalty rates.
Chapter 4 provides a review of the leading Public Health deals since 2010. Deals are listed by headline value. The chapter includes the top 25 most active Public Health dealmakers, together with a full listing of deals to which they are a party. Where the deal has an agreement contract published at the SEC a link provides online access to the contract.
Chapter 5 provides comprehensive access to Public Health deals since 2010 where a deal contract is available, providing the user with direct access to contracts as filed with the SEC regulatory authorities. Each deal title links via Weblink to an online version of the deal record contract document, providing easy access to each contract document on demand.
Chapter 6 provides a comprehensive directory of all Public Health partnering deals by specific Public Health target announced since 2010. The chapter is organized by specific Public Health therapeutic target. Each deal title links via Weblink to an online version of the deal record and where available, the contract document, providing easy access to each contract document on demand.
In addition, a comprehensive appendix is provided with each report of all Public Health partnering deals signed and announced since 2010. The appendices are organized by company A-Z, stage of development at signing, deal type (collaborative R&D, co-promotion, licensing etc) and technology type. Each deal title links via Weblink to an online version of the deal record and where available, the contract document, providing easy access to each contract document on demand.
The report also includes numerous tables and figures that illustrate the trends and activities in Public Health partnering and dealmaking since 2010.
In conclusion, this report provides everything a prospective dealmaker needs to know about partnering in the research, development and commercialization of Public Health technologies and products.
Global Public Health Partnering 2010 to 20200 is intended to provide the reader with an in-depth understanding and access to Public Health trends and structure of deals entered into by leading companies worldwide.
The report includes deals for the following indications: Addiction, Smoking, Drugs, Alcohol, Health education, Obesity, Preventative medicine, plus other public health indications.
Each deal title links via Weblink to an online version of the deal record and where available, the contract document, providing easy access to each contract document on demand.
- Trends in Public Health partnering deals
- Financial deal terms for headline, upfront and royalty by stage of development
- Public Health partnering agreement structure
- Public Health partnering contract documents
- Top Public Health deals by value
- Most active Public Health dealmakers
Most of the deals included within the report occur when a licensee obtains a right or an option right to license a licensor’s product or technology. More often these days these deals tend to be multi-component including both a collaborative R&D and a commercialization of outcomes element.
The report takes readers through the comprehensive Public Health disease deal trends, key players and top deal values allowing the understanding of how, why and under what terms companies are currently entering Public Health deals.
The report presents financial deal terms values for Public Health deals, where available listing by overall headline values, upfront payments, milestones and royalties enabling readers to analyse and benchmark the value of current deals.
The initial chapters of this report provide an orientation of Public Health dealmaking trends.
Chapter 1 provides an introduction to the report.
Chapter 2 provides an overview of the trends in Public Health dealmaking since 2010 covering trends by year, deal type, stage of development, technology type and therapeutic indication.
Chapter 3 includes an analysis of financial deal terms covering headline value, upfront payment, milestone payments and royalty rates.
Chapter 4 provides a review of the leading Public Health deals since 2010. Deals are listed by headline value. The chapter includes the top 25 most active Public Health dealmakers, together with a full listing of deals to which they are a party. Where the deal has an agreement contract published at the SEC a link provides online access to the contract.
Chapter 5 provides comprehensive access to Public Health deals since 2010 where a deal contract is available, providing the user with direct access to contracts as filed with the SEC regulatory authorities. Each deal title links via Weblink to an online version of the deal record contract document, providing easy access to each contract document on demand.
Chapter 6 provides a comprehensive directory of all Public Health partnering deals by specific Public Health target announced since 2010. The chapter is organized by specific Public Health therapeutic target. Each deal title links via Weblink to an online version of the deal record and where available, the contract document, providing easy access to each contract document on demand.
In addition, a comprehensive appendix is provided with each report of all Public Health partnering deals signed and announced since 2010. The appendices are organized by company A-Z, stage of development at signing, deal type (collaborative R&D, co-promotion, licensing etc) and technology type. Each deal title links via Weblink to an online version of the deal record and where available, the contract document, providing easy access to each contract document on demand.
The report also includes numerous tables and figures that illustrate the trends and activities in Public Health partnering and dealmaking since 2010.
In conclusion, this report provides everything a prospective dealmaker needs to know about partnering in the research, development and commercialization of Public Health technologies and products.
Report Scope
Global Public Health Partnering 2010 to 20200 is intended to provide the reader with an in-depth understanding and access to Public Health trends and structure of deals entered into by leading companies worldwide.
Global Public Health Partnering 2010 to 2020 includes:
- Trends in Public Health dealmaking in the biopharma industry since 2010
- Analysis of Public Health deal structure
- Access to headline, upfront, milestone and royalty data
- Access to hundreds of Public Health deal contract documents
- Comprehensive access to over 450 Public Health deal records
- The leading Public Health deals by value since 2010
- Most active Public Health dealmakers since 2010
The report includes deals for the following indications: Addiction, Smoking, Drugs, Alcohol, Health education, Obesity, Preventative medicine, plus other public health indications.
In Global Public Health Partnering 2010 to 2020, available deals and contracts are listed by:
- Headline value
- Upfront payment value
- Royalty rate value
- Stage of development at signing
- Deal component type
- Technology type
- Specific therapy indication
Each deal title links via Weblink to an online version of the deal record and where available, the contract document, providing easy access to each contract document on demand.
The Global Public Health Partnering 2010 to 20200 report provides comprehensive access to available deals and contract documents for over 450 public health deals. Analyzing actual contract agreements allows assessment of the following:
- What are the precise rights granted or optioned?
- What is actually granted by the agreement to the partner company?
- What exclusivity is granted?
- What is the payment structure for the deal?
- How are the sales and payments audited?
- What is the deal term?
- How are the key terms of the agreement defined?
- How are IPRs handled and owned?
- Who is responsible for commercialization?
- Who is responsible for development, supply, and manufacture?
- How is confidentiality and publication managed?
- How are disputes to be resolved?
- Under what conditions can the deal be terminated?
- What happens when there is a change of ownership?
- What sublicensing and subcontracting provisions have been agreed?
- Which boilerplate clauses does the company insist upon?
- Which boilerplate clauses appear to differ from partner to partner or deal type to deal type?
- Which jurisdiction does the company insist upon for agreement law?
Table of Contents
Executive SummaryChapter 1 – Introduction
Chapter 2 – Trends in Public Health dealmaking
Chapter 3 –Financial deal terms for Public Health partnering
Chapter 4 – Leading Public Health deals and dealmakers
Chapter 5 – Public Health contract document directory
Chapter 6 – Public Health dealmaking by therapeutic target
Appendices
Table of Figures
Companies Mentioned (Partial List)
A selection of companies mentioned in this report includes, but is not limited to:
- 22nd Century
- Abic Marketing
- Academy Medical
- Academy of Nutrition and Dietetics
- Accenture
- Acelrx Pharmaceuticals
- Achieve Life Science
- Actavis (acquired by Watson)
- Acura Pharmaceuticals
- Adapt Pharma
- Addex Therapeutics
- Addiction Institute of Mount Sinai
- ADL Bionatur Solutions
- Aetna
- Agilent Technologies
- Aiforia Technologies
- AIT Laboratories
- Akers Biosciences
- Albert Einstein College of Medicine
- AllianceRx Walgreens Prime
- Altasciences
- Altreos Research Partners
- Amarantus BioSciences
- Amazon Web Services
- American Dental Association
- Amygdala
- Annum Health
- Antidote Therapeutics
- AntiOp
- Apollo Endosurgery
- AppianRx
- Appriss Health
- Aptuit
- ARCH Personalized Medicine Initiative
- Arena Pharmaceuticals
- AstraZeneca
- AstraZeneca HealthCare Foundation
- AutoGenomics
- Avista Pharma Solutions
- Avricore Health
- Axsome Therapeutics
- Bain Capital
- BarioSurg
- Beacon Discovery
- Best Choice
- BioCorRx
- BioDelivery Sciences
- Biohit
- Biologix FZCo
- Biomedical Advanced Research and Development Authority
- BioViva Sciences
- Boehringer Ingelheim
- Braeburn Pharmaceuticals
- Brainsway
- Brigham and Women's Hospital
- C4X Discovery
- California Institute for Biomedical Research
- Camarus
- Cambridge Commodities
- Camino Pharma
- Canadian Institutes of Health Research
- Case Western Reserve University
- Celgene
- Centene
- Center on Addiction
- Centers for Disease Control and Prevention
- Cerecor
- Cerevel Therapeutics
- Cerner
- Cheplapharm Arzneimittel
- Chiesi Farmaceutici
- Chinmax Medical Systems
- Christiana Care Health System
- Chronos Therapeutics
- Chrono Therapeutics
- Cigna Healthcare
- City of Hope
- Cold Spring Harbor
- Collective Medical
- Collegium Pharmaceuticals
- Columbia University
- Consilient Health
- Crown Bioscience
- CTC Group
- CVS Caremark
- D&A Pharma
- Daiichi Sankyo
- Dent Neurologic Institute
- Department of Defense
- Department of Veterans Affairs
- Doping Control Center
- Dr. Reddy's Laboratories
- Duke University
- Edico Genome
- Egalet
- Eiger BioPharmaceuticals
- Eli Lilly
- Elithea Sciences
- Embark Biotech
- Embera NeuroTherapeutics
- Emisphere
- Energesis Pharmaceuticals
- Enteris Biopharma
- Enterome Bioscience
- EnteroMedics
- Eolas Therapeutics
- Eternygen
- Ethismos Research
- Euthymics Bioscience
- Evonik Industries
- Evotec
- Express Scripts
- Fairview Health System
- Fannin
- Food and Drug Administration (FDA)
- Galmed Pharmaceuticals
- Genentech
- Genewiz
- Genomas
- Gentag
- Gilead Sciences
- GlaxoSmithKline
- Global Center for Health Innovation
- Global Genomics Group
- Grunenthal
- Grupo Juste
- Gubra
- Harm Reduction Therapeutics
- HealthWarehouse
- Helsinki University Central Hospital (HUCH) Comprehensive Cancer Center
- Heptares Therapeutics
- Heron Therapeutics
- Highland Pharmaceutical
- Hisamitsu Pharmaceutical
- Hy Laboratories
- IBM
- India Globalization Capital
- Indivior
- Inflexxion
- Inovalon
- iNova Pharmaceuticals
- Inspirion Delivery Sciences
- InstaNatural
- Intarcia Therapeutics
- Interpace Diagnostics Group
- Intrexon
- inVentiv Health
- Itamar Medical
- Jackson Laboratory
- Janssen Pharmaceuticals
- Janssen Pharmaceutica NV
- John Morley Foods
- Johnson & Johnson Innovation
- Joslin Diabetes Center
- Jubilant Biosys
- Kaiser Permanente
- Kallyope
- KeyBioScience
- Klaria
- Knighton Foods
- Knight Therapeutics
- Kolar Filtration
- KSF Acquisition
- KVK-Tech
- Kwang Dong Pharmaceutical
- Laboratory Corporation of America
- LCS Therapeutics
- Lifeloc Technologies
- Ligand Pharmaceuticals
- Lightlake Therapeutics
- Lucerne Biosciences
- Lucideon
- Lupin Limited
- Lyra Health
- Marker Test Diagnostics
- Martindale Pharma
- Massachusetts General Hospital
- Maverix Biomics
- Mayo Clinic
- MD Anderson Cancer Center
- MediCann Handels
- MediciNova
- MedImmune
- Medison Pharma
- Medix
- Merck and Co
- Merck KGaA
- Metabasis Therapeutics
- Metabolix
- Michigan State University
- Minneapolis Medical Research Foundation
- Molecular You
- Molteni Farmaceutici
- Montefiore Health System
- Morel Company
- Moyer Foundation
- Mundipharma
- NASCO Products
- National Academy of Medicine
- National Cancer Institute
- National Center for Advancing Translational Sciences (NCATS)
- National Center for Complementary and Integrative Health
- National Institute on Alcohol Abuse and Alcoholism (NIAAA)
- National Institute on Drug Abuse (NIDA)
- National Institutes of Health
- Navamedic
- NEMUS Bioscience
- NeuroSearch
- Nevada Center For Behavioral Health
- New York State
- New York University
- NGM Biopharmaceuticals
- NMS Labs
- North Georgia Healthcare
- Novartis Consumer Health
- Novo Nordisk
- Novu
- Numab
- Nutriband
- Nutricion
- Obalon Therapeutics
- OncoGenex Pharmaceuticals
- Ontario Institute for Cancer Research
- Opiant Pharmaceuticals
- Opisafe
- OptiBiotix
- Oregon Health Sciences University
- Orexigen Therapeutics
- Orexo
- Ortho-Clinical Diagnostics
- Pacific Medical
- Patheon
- PDL BioPharma
- PEAR Therapeutics
- Perelman School of Medicine
- Pernix Therapeutics
- Perrigo
- Pfizer
- Pharmathen
- PinneyAssociates
- Premier Biomedical
- PreveCeutical Medical
- Productos Medix
- Publicis Healthcare Communications Group
- Purdue Pharma
- Quintiles
- Rainbow Coral
- Reckitt Benckiser
- ReShape Lifesciences
- ReShape Medical
- Rhythm Pharmaceuticals
- RS EDEN
- RTI International
- Salix Pharmaceuticals
- Samsung Electronics
- Sandia National Laboratories
- Sandoz
- Sanford Burnham Institute
- Saniona
- Sanofi
- Satori
- Second Genome
- Selecta Biosciences
- Semmelweis University
- Seres Therapeutics
- Sizewise Worldwide
- SkyePharma
- Smith Medical Partners
- Smoker Friendly International
- Sono Bello
- Sound Affects Life
- Stanford University
- StemoniX
- Stevia First
- Sun Pharmaceutical
- Sure med Compliance
- Targeted Medical Pharma
- Tenet Diagnostics
- Teva Pharmaceutical Industries
- The Alchemists Kitchen
- The Obesity Society
- The Recovery Platform
- Thermo Fisher Scientific
- Titan Pharmaceuticals
- TONIX Pharmaceuticals
- UfaceME
- UniQuest
- University of Auckland
- University of Bristol
- University of California
- San Diego
- University of Chicago
- University of Houston
- University of Mississippi
- University of Rochester
- US Department of Veteran Affairs
- US WorldMeds
- Valeant Pharmaceuticals
- VDM Biochemicals
- Viking Therapeutics
- Vince & Associates Clinical Research
- Viome
- Vitae Pharmaceuticals
- Vivus
- Vizient
- W2O
- Washington University in St Louis
- WuXi NextCODE Genomics
- Xenoport
Methodology
- The publisher reports provide insight into the trends and terms of partnering deals in the global life sciences sector.
- The publisher reports are updated every six months to ensure the user has access to the latest announcements and trends in the topic focus of the report.
- The publisher analysts review the deal data to provide an overview and analysis of deal trends, including example deals and terms.
- The publisher reports source deal data from our proprietary deals and alliances database. The database is updated daily by our analysts with new deals as they are announced globally by the company’s party to the deal.
- The data in the deals and alliances database is obtained from secondary sources such as publicly available industry sources including press releases, company presentations, investor presentations, company SEC filings, other company filings, company websites, conference presentations. Sources are identified to allow for user verification.
The publisher provides comprehensive coverage of the following partnering or deal types:
- Asset purchase
- Assignment
- Co-development
- Co-market
- Co-promotion
- Collaborative R&D
- Contract service
- CRADA
- Cross-licensing
- Development
- Distribution
- Equity purchase
- Evaluation
- Grant
- Joint venture
- Licensing
- Loan
- Manufacturing
- Marketing
- Option
- Promotion
- Research
- Royalty financing
- Settlement
- Spin out
- Sub license
- Supply
- Termination
- Warrant
Every deal record is fully categorized and includes the following data, where available:
- Industry sector
- Therapy areas
- Technology type
- Deal components
- Financial terms
- Stage of development
- Exclusivity
- Asset type
- Geographic focus
- Excluded geography
- Company press release
- SEC filing data including contract document
All financial amounts are converted to US$ using the exchange rate available on the date of deal announcement, enabling direct comparison of deal terms across international territories.
LOADING...
